If You Invested in Syndax Pharmaceuticals Inc (SNDX)

Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) is a commercial-stage biopharmaceutical company focused on advancing cancer therapies. According to the company’s disclosures, Syndax centers its efforts on developing and commercializing targeted medicines for hematologic malignancies and related immune-mediated conditions. The company highlights a pipeline led by two U.S. Food and Drug Administration (FDA)-approved products: Revuforj® (revumenib), an oral menin inhibitor, and Niktimvo™ (axatilimab-csfr), a monoclonal antibody that blocks the colony stimulating factor 1 (CSF‑1) receptor.

Core business and therapeutic focus

Syndax describes itself as a commercial-stage biopharmaceutical company advancing cancer therapies across the treatment continuum. Its business is built around discovering, developing, and commercializing medicines that address defined molecular or immunologic drivers of disease. The company’s activities are anchored in the United States, and it reports its common stock trading on Nasdaq under the symbol SNDX.

The company’s lead products target areas of high unmet need in oncology and immune complications of cancer treatment. Revuforj (revumenib) is FDA approved for relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation, and for relapsed or refractory acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 (NPM1) mutation in adult and pediatric patients one year and older who have no satisfactory alternative treatment options. Niktimvo (axatilimab‑csfr) is FDA approved in the United States for chronic graft‑versus‑host disease (GVHD) after failure of at least two prior lines of systemic therapy in adult and pediatric patients above a specified weight threshold.

Revuforj® (revumenib) and menin inhibition

Revuforj is described by Syndax as an oral, first‑in‑class menin inhibitor. The company notes that multiple trials of revumenib are ongoing or planned across the acute leukemia treatment landscape, including in combination with standard-of-care therapies in newly diagnosed patients with NPM1‑mutated (NPM1m) or KMT2A‑rearranged (KMT2Ar) AML. These include pivotal Phase 3 trials such as EVOLVE‑2 and REVEAL‑ND, as well as investigator‑sponsored and collaborative studies like SAVE, BEAT AML, and other frontline and post‑transplant maintenance settings.

Syndax reports that revumenib has received several regulatory designations. The U.S. FDA previously granted Orphan Drug Designation for AML, acute lymphoblastic leukemia (ALL) and acute leukemias of ambiguous lineage (ALAL), Fast Track designation for adult and pediatric patients with relapsed or refractory acute leukemias harboring a KMT2A rearrangement or NPM1 mutation, and Breakthrough Therapy Designation for adult and pediatric patients with relapsed or refractory acute leukemia harboring a KMT2A rearrangement. The European Commission has also granted Orphan Drug Designation for AML.

The company also highlights real‑world and clinical data for revumenib, including use in relapsed or refractory NPM1m, KMT2Ar and NUP98‑rearranged acute leukemias, in combination regimens with venetoclax and hypomethylating agents, and as post‑hematopoietic stem cell transplant (HSCT) maintenance in children with HOX‑driven AML. Presentations at the American Society of Hematology (ASH) Annual Meeting have showcased response rates, measurable residual disease (MRD) negativity, and tolerability across multiple settings.

Niktimvo™ (axatilimab‑csfr) and CSF‑1R blockade

Niktimvo (axatilimab‑csfr) is characterized as a first‑in‑class colony stimulating factor‑1 receptor (CSF‑1R)‑blocking antibody approved in the U.S. for chronic GVHD after failure of at least two prior lines of systemic therapy in eligible adult and pediatric patients. Syndax licensed exclusive worldwide rights to develop and commercialize axatilimab from UCB in 2016. In 2021, Syndax and Incyte entered into an exclusive worldwide co‑development and co‑commercialization license agreement for axatilimab in chronic GVHD and any future indications.

Axatilimab is being evaluated in multiple clinical studies. These include frontline combination trials in chronic GVHD, such as a Phase 2 trial with ruxolitinib and a pivotal Phase 3 trial with corticosteroids, as well as a Phase 2 trial in idiopathic pulmonary fibrosis (IPF). Abstracts accepted for ASH 2025 describe safety, long‑term treatment duration, and feasibility of different dosing schedules in chronic GVHD, as well as exploratory work in other hematologic contexts.

Pipeline, clinical development, and collaborations

Syndax reports that it is conducting several clinical trials across the continuum of treatment for acute leukemias and chronic GVHD. For revumenib, the company and its collaborators are studying combinations with venetoclax, azacitidine, decitabine/cedazuridine, intensive chemotherapy regimens, and post‑transplant maintenance strategies. Trials span relapsed or refractory disease, newly diagnosed patients unfit for intensive chemotherapy, and fit patients receiving intensive induction and consolidation regimens.

For axatilimab, Syndax and its partner Incyte are co‑developing the antibody in chronic GVHD and exploring its potential in IPF and other settings. The company notes that it records a share of Niktimvo net commercial profit, defined in its disclosures as net product revenue minus cost of sales and commercial expenses, under the collaboration arrangement.

Syndax also describes a collaboration with the World Orphan Drug Alliance (WODA) to expand access to Revuforj outside the United States through a multi‑regional Managed Access Program. This program is being launched in parts of Eurasia, Central and Southeast Europe, Israel, the Middle East and Turkey, Latin America, and Africa, enabling physicians to prescribe Revuforj to appropriate patients in regions where the drug is not yet commercially available but access to novel medicines is permitted by local regulations and funding can be secured.

Regulatory and commercial status

The company’s SEC filings and press releases confirm that Syndax remains listed on Nasdaq under the symbol SNDX and continues to file periodic and current reports, including Forms 8‑K related to financial results and regulatory milestones. An October 24, 2025 Form 8‑K describes FDA approval of Revuforj for relapsed or refractory AML with a susceptible NPM1 mutation in specified adult and pediatric patients. Other 8‑K filings reference quarterly financial results and board changes.

Syndax characterizes 2025 as a transformational period in which it secured a third FDA approval and executed commercial launches of Revuforj and Niktimvo. The company reports growing product revenues from Revuforj and Niktimvo‑related collaboration income, and states that it is advancing toward profitability, supported by its cash position, anticipated product revenue and interest income, and a stable operating expense base.

Risk profile and safety considerations

The company’s product communications emphasize important safety information for Revuforj, including boxed warnings for differentiation syndrome, QTc prolongation, and Torsades de Pointes, as well as embryo‑fetal toxicity. Syndax outlines adverse reactions observed in clinical trials, guidance on monitoring and dose modification, and cautions regarding drug interactions, pregnancy, lactation, and specific populations. These risk disclosures form a key part of the company’s regulatory and clinical profile.

Position within the pharmaceutical preparation manufacturing sector

Within the pharmaceutical preparation manufacturing industry, Syndax operates as a commercial‑stage biopharmaceutical company with a focus on oncology and immune complications of cancer treatment. Its activities span discovery, clinical development, regulatory engagement, commercialization, and global access initiatives for targeted biologics and small molecules. The company’s emphasis on menin inhibition and CSF‑1R blockade, along with multiple ongoing clinical programs and collaborations, defines its role in the broader manufacturing sector for specialized therapeutic products.

FAQs about Syndax Pharmaceuticals (SNDX)

• What does Syndax Pharmaceuticals do?
  Syndax Pharmaceuticals is a commercial‑stage biopharmaceutical company advancing cancer therapies. It focuses on developing and commercializing medicines such as Revuforj (revumenib), an FDA‑approved menin inhibitor for certain relapsed or refractory acute leukemias, and Niktimvo (axatilimab‑csfr), an FDA‑approved CSF‑1R‑blocking antibody for chronic graft‑versus‑host disease after at least two prior systemic therapies.
• Which diseases are targeted by Syndax’s lead products?
  Revuforj targets relapsed or refractory acute leukemia with a KMT2A translocation and relapsed or refractory AML with a susceptible NPM1 mutation in eligible adult and pediatric patients. Niktimvo is approved in the United States for chronic graft‑versus‑host disease after failure of at least two prior lines of systemic therapy in adult and pediatric patients above a specified weight.
• How is Revuforj (revumenib) being developed beyond its current indication?
  Syndax reports multiple ongoing or planned trials of revumenib across the acute leukemia treatment continuum, including combinations with venetoclax and hypomethylating agents, intensive chemotherapy regimens, and post‑transplant maintenance. These studies span relapsed or refractory disease, newly diagnosed patients unfit for intensive chemotherapy, and fit patients receiving intensive regimens.
• What collaborations support Syndax’s pipeline?
  Syndax has an exclusive worldwide license from UCB to develop and commercialize axatilimab and a worldwide co‑development and co‑commercialization agreement with Incyte for axatilimab in chronic GVHD and future indications. The company also collaborates with clinical trial networks, academic centers, and organizations such as the World Orphan Drug Alliance to support clinical development and access programs.
• How does Syndax generate revenue from Niktimvo?
  Under its agreement with Incyte, Syndax records a share of Niktimvo net commercial profit, which it defines as net product revenue minus cost of sales and commercial expenses. This share is reported as collaboration revenue in the company’s financial results.
• What regulatory designations has revumenib received?
  Revumenib has received Orphan Drug Designation from the U.S. FDA for AML, ALL, and ALAL and from the European Commission for AML. The U.S. FDA has also granted Fast Track designation for adult and pediatric patients with relapsed or refractory acute leukemias harboring a KMT2A rearrangement or NPM1 mutation, and Breakthrough Therapy Designation for adult and pediatric patients with relapsed or refractory acute leukemia harboring a KMT2A rearrangement.
• Is Syndax Pharmaceuticals still publicly traded?
  Yes. Syndax’s press releases and SEC filings describe the company as trading on Nasdaq under the symbol SNDX and continuing to file current reports such as Forms 8‑K related to financial results, regulatory approvals, and corporate governance matters.
• Does Syndax operate outside the United States?
  Syndax states that its business activity is conducted through the United States, but it is also working with the World Orphan Drug Alliance to launch a multi‑regional Managed Access Program for Revuforj in parts of Eurasia, Central and Southeast Europe, Israel, the Middle East and Turkey, Latin America, and Africa, where local regulations and funding permit access to novel medicines.